Nanologica & Sterling partnership furthers new business venture

Nanologica AB has entered into a service agreement with global contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions for the large-scale production of silica particles.

The partnership is the latest step in the development of a new business venture for Nanologica, which specialises in the development and manufacture of silica for application in drug delivery and chromatography. Using Nanologica’s technology, UK-based Sterling Pharma Solutions will produce the large volumes of NLAB Saga™ chromatography material needed to perform preparative chromatography.

Nanologica announced in February 2018 that it will start manufacturing preparatory chromatography media. Preparative chromatography is used in pharmaceutical manufacturing to “purify” peptides, specifically insulin. Vastly greater amounts of silica are used in preparative chromatography than in analytical chromatography, where Nanologica is active today.

Sterling Pharma Solutions, based in the North East of England, is a well-established manufacturer of active substances, materials and products for customers in the pharmaceutical industry.

Kevin Cook, CEO of Sterling Pharma Solutions said: “Sterling is delighted to be working with Nanologica on this exciting and innovative opportunity. Sterling has rich experience in the development and scale-up of complex synthesis in a fully cGMP environment. The combination of the Nanolologica expertise and technology, together with Sterling’s manufacturing capabilities, provides the required combination for successful commercialisation.”